Last 12 months
Inside the activity.
0 purchase rows · 31 sale rows
Disclosed non-derivative P/S rows, by transaction month. Includes amendments and private transactions.Monthly counts
| Month | Purchases | Sales |
|---|---|---|
| Nov 2025 | 0 | 5 |
| Dec 2025 | 0 | 4 |
| Jan 2026 | 0 | 4 |
| Feb 2026 | 0 | 4 |
| Mar 2026 | 0 | 3 |
| Apr 2026 | 0 | 3 |
| May 2026 | 0 | 1 |
| Jun 2026 | 0 | 1 |
| Jul 2026 | 0 | 1 |
| Aug 2026 | 0 | 2 |
| Sep 2026 | 0 | 2 |
| Oct 2026 | 0 | 1 |
Latest available
Insider transactions
Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Owner / reported role | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| October 29, 2018 Filed Oct 30, 2018 22:06 UTC |
Sodhi RajwantPresident, SaaS Business
|
GrantResMed Common Stock | 2,296 | $0.00 | $0.00 |
DisclosureSEC source: 0001567619-18-004799 · doc1.xml · nonDerivative · entry 1 Sodhi Rajwant · CIK 0001715325 · President, SaaS Business 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 37,534 F1 · shares: Represents performance-based restricted stock units granted on November 16, 2017. The shares were earned on October 29, 2018, when the compensation committee certified that the performance metrics were met. The earned units remain subject to time-vesting requirements, and are scheduled to vest on the three-year anniversary of the grant, assuming continued service through the vesting date. Read SEC document |
| October 29, 2018 Filed Oct 30, 2018 21:54 UTC |
PENDARVIS DAVIDChief Administrative Officer
|
GrantResMed Common Stock | 2,789 | $0.00 | $0.00 |
DisclosureSEC source: 0001567619-18-004798 · doc1.xml · nonDerivative · entry 1 PENDARVIS DAVID · CIK 0001196723 · Chief Administrative Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 107,040 F1 · shares: Represents performance-based restricted stock units granted on November 16, 2017. The shares were earned on October 29, 2018, when the compensation committee certified that the performance metrics were met. The earned units remain subject to time-vesting requirements, and are scheduled to vest on the three-year anniversary of the grant, assuming continued service through the vesting date. Read SEC document |
| October 29, 2018 Filed Oct 30, 2018 21:53 UTC |
Hollingshead JamesPresident, Americas
|
GrantResMed Common Stock | 3,281 | $0.00 | $0.00 |
DisclosureSEC source: 0001567619-18-004797 · doc1.xml · nonDerivative · entry 1 Hollingshead James · CIK 0001570610 · President, Americas 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 73,904 F1 · shares: Represents performance-based restricted stock units granted on November 16, 2017. The shares were earned on October 29, 2018, when the compensation committee certified that the performance metrics were met. The earned units remain subject to time-vesting requirements, and are scheduled to vest on the three-year anniversary of the grant, assuming continued service through the vesting date. Read SEC document |
| October 29, 2018 Filed Oct 30, 2018 21:52 UTC |
Sandercock BrettChief Financial Officer
|
GrantResMed Common Stock | 2,789 | $0.00 | $0.00 |
DisclosureSEC source: 0001567619-18-004795 · doc1.xml · nonDerivative · entry 1 Sandercock Brett · CIK 0001346064 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 74,021 F1 · shares: Represents performance-based restricted stock units granted on November 16, 2017. The shares were earned on October 29, 2018, when the compensation committee certified that the performance metrics were met. The earned units remain subject to time-vesting requirements, and are scheduled to vest on the three-year anniversary of the grant, assuming continued service through the vesting date. Read SEC document |
| October 29, 2018 Filed Oct 30, 2018 21:52 UTC |
McHale RichardPresident, RC Business
|
GrantResMed Common Stock | 1,968 | $0.00 | $0.00 |
DisclosureSEC source: 0001567619-18-004794 · doc1.xml · nonDerivative · entry 1 McHale Richard · CIK 0001715326 · President, RC Business 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 21,610 F1 · shares: Represents performance-based restricted stock units granted on November 16, 2017. The shares were earned on October 29, 2018, when the compensation committee certified that the performance metrics were met. The earned units remain subject to time-vesting requirements, and are scheduled to vest on the three-year anniversary of the grant, assuming continued service through the vesting date. Read SEC document |
| October 29, 2018 Filed Oct 30, 2018 21:51 UTC |
Farrell Michael J.Chief Executive Officer
|
GrantResMed Common Stock | 11,155 | $0.00 | $0.00 |
DisclosureSEC source: 0001567619-18-004793 · doc1.xml · nonDerivative · entry 1 Farrell Michael J. · CIK 0001485164 · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 256,291 F1 · shares: Represents performance-based restricted stock units granted on November 16, 2017. The shares were earned on October 29, 2018, when the compensation committee certified that the performance metrics were met. The earned units remain subject to time-vesting requirements, and are scheduled to vest on the three-year anniversary of the grant, assuming continued service through the vesting date. Read SEC document |
| October 29, 2018 Filed Oct 30, 2018 21:50 UTC |
Douglas Robert AndrewPresident and COO ResMed Inc.
|
GrantResMed Common Stock | 7,382 | $0.00 | $0.00 |
DisclosureSEC source: 0001567619-18-004792 · doc1.xml · nonDerivative · entry 1 Douglas Robert Andrew · CIK 0001352232 · President and COO ResMed Inc. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 63,688 F1 · shares: Represents performance-based restricted stock units granted on November 16, 2017. The shares were earned on October 29, 2018, when the compensation committee certified that the performance metrics were met. The earned units remain subject to time-vesting requirements, and are scheduled to vest on the three-year anniversary of the grant, assuming continued service through the vesting date. Read SEC document |
| October 15, 2018 Filed Oct 17, 2018 17:09 UTC |
Sandercock BrettChief Financial Officer
|
SaleResMed Common Stock | 2,000 | $103.16 | $206,320.00 |
DisclosureSEC source: 0001567619-18-004215 · doc1.xml · nonDerivative · entry 1 Sandercock Brett · CIK 0001346064 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 71,232 F1 · kind: The transaction was conducted under a Rule 10b5-1 Plan. Read SEC document |
| October 03, 2018 Filed Oct 4, 2018 20:17 UTC |
PENDARVIS DAVIDChief Administrative Officer
|
Exercise / conversionResMed Common Stock Options · Derivative | 2,810 | $0.00 Strike: $38.98 | $0.00 |
DisclosureSEC source: 0001567619-18-003710 · doc1.xml · derivative · entry 3 PENDARVIS DAVID · CIK 0001196723 · Chief Administrative Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,810 Underlying: ResMed Common Stock · 2,810 shares Expires 2019-11-15 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transaction was conducted under a Rule 10b5-1 plan. F2 · derivative.exercise_date: Represents date options first became exercisable. Options vest 1/3 per year. Read SEC document |
| October 03, 2018 Filed Oct 4, 2018 20:17 UTC |
PENDARVIS DAVIDChief Administrative Officer
|
SaleResMed Common Stock | 2,810 | $113.95 | $320,199.50 |
DisclosureSEC source: 0001567619-18-003710 · doc1.xml · nonDerivative · entry 2 PENDARVIS DAVID · CIK 0001196723 · Chief Administrative Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 104,251 F1 · kind: The transaction was conducted under a Rule 10b5-1 plan. Read SEC document |
| October 03, 2018 Filed Oct 4, 2018 20:17 UTC |
PENDARVIS DAVIDChief Administrative Officer
|
Exercise / conversionResMed Common Stock | 2,810 | $38.98 | $109,533.80 |
DisclosureSEC source: 0001567619-18-003710 · doc1.xml · nonDerivative · entry 1 PENDARVIS DAVID · CIK 0001196723 · Chief Administrative Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 107,061 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transaction was conducted under a Rule 10b5-1 plan. Read SEC document |
| October 01, 2018 Filed Oct 3, 2018 21:59 UTC |
Hollingshead JamesPresident, Sleep Business
|
SaleResMed Common Stock | 600 | $115.88 | $69,528.00 |
DisclosureSEC source: 0001567619-18-003661 · doc1.xml · nonDerivative · entry 1 Hollingshead James · CIK 0001570610 · President, Sleep Business 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 70,623 F1 · kind: The transaction was conducted under a Rule 10b5-1 Plan. F1 · price: The transaction was conducted under a Rule 10b5-1 Plan. F1 · balance_after: The transaction was conducted under a Rule 10b5-1 Plan. Read SEC document |
| September 17, 2018 Filed Sep 18, 2018 23:13 UTC |
Sandercock BrettChief Financial Officer
|
SaleResMed Common Stock | 2,000 | $114.30 | $228,600.00 |
DisclosureSEC source: 0001567619-18-002849 · doc1.xml · nonDerivative · entry 1 Sandercock Brett · CIK 0001346064 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 73,232 F1 · kind: The transaction was conducted under a Rule 10b5-1 Plan. Read SEC document |
| September 04, 2018 Filed Sep 5, 2018 17:59 UTC |
PENDARVIS DAVIDChief Administrative Officer
|
Exercise / conversionResMed Common Stock Options · Derivative | 2,810 | $0.00 Strike: $38.98 | $0.00 |
DisclosureSEC source: 0001567619-18-002120 · doc1.xml · derivative · entry 3 PENDARVIS DAVID · CIK 0001196723 · Chief Administrative Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,620 Underlying: ResMed Common Stock · 2,810 shares Expires 2019-11-15 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transaction was conducted under a Rule 10b5-1 plan. F2 · derivative.exercise_date: Represents date options first became exercisable. Options vest 1/3 per year. Read SEC document |
| September 04, 2018 Filed Sep 5, 2018 17:59 UTC |
PENDARVIS DAVIDChief Administrative Officer
|
SaleResMed Common Stock | 2,810 | $111.26 | $312,640.60 |
DisclosureSEC source: 0001567619-18-002120 · doc1.xml · nonDerivative · entry 2 PENDARVIS DAVID · CIK 0001196723 · Chief Administrative Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 104,251 F1 · kind: The transaction was conducted under a Rule 10b5-1 plan. Read SEC document |
| September 04, 2018 Filed Sep 5, 2018 17:59 UTC |
PENDARVIS DAVIDChief Administrative Officer
|
Exercise / conversionResMed Common Stock | 2,810 | $38.98 | $109,533.80 |
DisclosureSEC source: 0001567619-18-002120 · doc1.xml · nonDerivative · entry 1 PENDARVIS DAVID · CIK 0001196723 · Chief Administrative Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 107,061 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transaction was conducted under a Rule 10b5-1 plan. Read SEC document |
| September 04, 2018 Filed Sep 5, 2018 17:58 UTC |
Hollingshead JamesPresident, Sleep Business
|
SaleResMed Common Stock | 600 | $111.59 | $66,954.00 |
DisclosureSEC source: 0001567619-18-002119 · doc1.xml · nonDerivative · entry 1 Hollingshead James · CIK 0001570610 · President, Sleep Business 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 71,223 F1 · kind: The transaction was conducted under a Rule 10b5-1 Plan. F1 · price: The transaction was conducted under a Rule 10b5-1 Plan. F1 · balance_after: The transaction was conducted under a Rule 10b5-1 Plan. Read SEC document |
| August 15, 2018 Filed Aug 16, 2018 23:42 UTC |
PENDARVIS DAVIDChief Administrative Officer
|
GrantResMed Common Stock | 5,168 | $0.00 | $0.00 |
DisclosureSEC source: 0001567619-18-001320 · doc1.xml · nonDerivative · entry 1 PENDARVIS DAVID · CIK 0001196723 · Chief Administrative Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 104,251 F1 · shares: Represents performance-based restricted stock units granted on November 16, 2017. The shares were earned on August 15, 2018, when the compensation committee certified that the performance metrics were met. Read SEC document |
| August 15, 2018 Filed Aug 17, 2018 00:20 UTC |
Farrell Michael J.Chief Executive Officer
|
GrantResMed Common Stock | 20,671 | $0.00 | $0.00 |
DisclosureSEC source: 0001567619-18-001328 · doc1.xml · nonDerivative · entry 1 Farrell Michael J. · CIK 0001485164 · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 245,136 F1 · shares: Represents performance-based restricted stock units granted on November 16, 2017. The shares were earned on August 15, 2018, when the compensation committee certified that the performance metrics were met. F2 · balance_after: Includes 69.99 shares of ResMed stock purchased on April 30,2018, through the ResMed Employee Stock Purchase Plan. Read SEC document |
| August 15, 2018 Filed Aug 16, 2018 23:52 UTC |
Douglas Robert AndrewPresident and COO ResMed Inc.
|
GrantResMed Common Stock | 13,679 | $0.00 | $0.00 |
DisclosureSEC source: 0001567619-18-001327 · doc1.xml · nonDerivative · entry 1 Douglas Robert Andrew · CIK 0001352232 · President and COO ResMed Inc. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 56,306 F1 · shares: Represents performance-based restricted stock units initially granted on November 16, 2017. The shares were earned on August 15, 2018, when the compensation committee certified that the performance metrics were met. Read SEC document |
| August 15, 2018 Filed Aug 16, 2018 23:11 UTC |
Sandercock BrettChief Financial Officer
|
GrantResMed Common Stock | 12,160 | $0.00 | $0.00 |
DisclosureSEC source: 0001567619-18-001318 · doc1.xml · nonDerivative · entry 2 Sandercock Brett · CIK 0001346064 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 75,232 F2 · shares: Represents performance-based restricted stock units granted on November 16, 2017. The shares were earned on August 15, 2018, when the compensation committee certified that the performance metrics were met. Read SEC document |
| August 15, 2018 Filed Aug 16, 2018 23:11 UTC |
Sandercock BrettChief Financial Officer
|
SaleResMed Common Stock | 2,000 | $107.45 | $214,900.00 |
DisclosureSEC source: 0001567619-18-001318 · doc1.xml · nonDerivative · entry 1 Sandercock Brett · CIK 0001346064 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 63,072 F1 · kind: The transaction was conducted under a Rule 10b5-1 Plan. Read SEC document |
| August 15, 2018 Filed Aug 17, 2018 16:51 UTC |
Sodhi RajwantPresident, SaaS Business
|
GrantResMed Common Stock | 8,512 | $0.00 | $0.00 |
DisclosureSEC source: 0001567619-18-001351 · doc1.xml · nonDerivative · entry 1 Sodhi Rajwant · CIK 0001715325 · President, SaaS Business 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 35,238 F1 · shares: Represents performance-based restricted stock units granted on November 16, 2017. The shares were earned on August 15, 2018, when the compensation committee certified that the performance metrics were met. F2 · balance_after: Includes 169.40 shares of ResMed stock purchased on April 30,2018, through the ResMed Employee Stock Purchase Plan. Read SEC document |
| August 15, 2018 Filed Aug 17, 2018 16:50 UTC |
Hollingshead JamesPresident, Americas
|
GrantResMed Common Stock | 12,160 | $0.00 | $0.00 |
DisclosureSEC source: 0001567619-18-001350 · doc1.xml · nonDerivative · entry 1 Hollingshead James · CIK 0001570610 · President, Americas 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 71,823 F1 · shares: Represents performance-based restricted stock units granted on November 16, 2017. The shares were earned on August 15, 2018, when the compensation committee certified that the performance metrics were met. Read SEC document |
| August 15, 2018 Filed Aug 17, 2018 16:49 UTC |
McHale RichardPresident, RC Business
|
GrantResMed Common Stock | 7,296 | $0.00 | $0.00 |
DisclosureSEC source: 0001567619-18-001349 · doc1.xml · nonDerivative · entry 1 McHale Richard · CIK 0001715326 · President, RC Business 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 19,642 F1 · shares: Represents performance-based restricted stock units granted on November 16, 2017. The shares were earned on August 15, 2018, when the compensation committee certified that the performance metrics were met. F2 · balance_after: Includes 142.65 shares of ResMed stock purchased on April 30,2018, through the ResMed Employee Stock Purchase Plan. Read SEC document |
| August 03, 2018 Filed Aug 6, 2018 18:47 UTC |
PENDARVIS DAVIDChief Administrative Officer
|
Exercise / conversionResMed Common Stock Options · Derivative | 2,810 | $0.00 Strike: $38.98 | $0.00 |
DisclosureSEC source: 0001140361-18-035561 · doc1.xml · derivative · entry 3 PENDARVIS DAVID · CIK 0001196723 · Chief Administrative Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,430 Underlying: ResMed Common Stock · 2,810 shares Expires 2019-11-15 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transaction was conducted under a Rule 10b5-1 plan. F2 · derivative.exercise_date: Represents date options first became exercisable. Options vest 1/3 per year. Read SEC document |
| August 03, 2018 Filed Aug 6, 2018 18:47 UTC |
PENDARVIS DAVIDChief Administrative Officer
|
SaleResMed Common Stock | 2,810 | $106.20 | $298,422.00 |
DisclosureSEC source: 0001140361-18-035561 · doc1.xml · nonDerivative · entry 2 PENDARVIS DAVID · CIK 0001196723 · Chief Administrative Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 99,083 F1 · kind: The transaction was conducted under a Rule 10b5-1 plan. Read SEC document |
| August 03, 2018 Filed Aug 6, 2018 18:47 UTC |
PENDARVIS DAVIDChief Administrative Officer
|
Exercise / conversionResMed Common Stock | 2,810 | $38.98 | $109,533.80 |
DisclosureSEC source: 0001140361-18-035561 · doc1.xml · nonDerivative · entry 1 PENDARVIS DAVID · CIK 0001196723 · Chief Administrative Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 101,893 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transaction was conducted under a Rule 10b5-1 plan. Read SEC document |
| August 01, 2018 Filed Aug 2, 2018 17:29 UTC |
Hollingshead JamesPresident, Sleep Business
|
SaleResMed Common Stock | 600 | $105.93 | $63,558.00 |
DisclosureSEC source: 0001140361-18-035061 · doc1.xml · nonDerivative · entry 1 Hollingshead James · CIK 0001570610 · President, Sleep Business 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 59,663 F1 · kind: The transaction was conducted under a Rule10b5-1 Plan. F1 · price: The transaction was conducted under a Rule10b5-1 Plan. F1 · balance_after: The transaction was conducted under a Rule10b5-1 Plan. Read SEC document |
| July 16, 2018 Filed Jul 17, 2018 18:05 UTC |
Sandercock BrettChief Financial Officer
|
SaleResMed Common Stock | 2,000 | $109.01 | $218,020.00 |
DisclosureSEC source: 0001140361-18-032693 · doc1.xml · nonDerivative · entry 1 Sandercock Brett · CIK 0001346064 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 65,072 F1 · kind: The transaction was conducted under a Rule 10b5-1 Plan. Read SEC document |
| July 03, 2018 Filed Jul 5, 2018 23:20 UTC |
PENDARVIS DAVIDChief Administrative Officer
|
Exercise / conversionResMed Common Stock Options · Derivative | 2,810 | $0.00 Strike: $38.98 | $0.00 |
DisclosureSEC source: 0001140361-18-031706 · doc1.xml · derivative · entry 3 PENDARVIS DAVID · CIK 0001196723 · Chief Administrative Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,240 Underlying: ResMed Common Stock · 2,810 shares Expires 2019-11-15 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: Represents date options first became exercisable. Options vest 1/3 per year. Read SEC document |
| July 03, 2018 Filed Jul 5, 2018 23:20 UTC |
PENDARVIS DAVIDChief Administrative Officer
|
SaleResMed Common Stock | 2,810 | $103.90 | $291,959.00 |
DisclosureSEC source: 0001140361-18-031706 · doc1.xml · nonDerivative · entry 2 PENDARVIS DAVID · CIK 0001196723 · Chief Administrative Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 99,083 F1 · kind: The transaction was conducted under a Rule 10b5-1 plan. Read SEC document |
| July 03, 2018 Filed Jul 5, 2018 23:20 UTC |
PENDARVIS DAVIDChief Administrative Officer
|
Exercise / conversionResMed Common Stock | 2,810 | $38.98 | $109,533.80 |
DisclosureSEC source: 0001140361-18-031706 · doc1.xml · nonDerivative · entry 1 PENDARVIS DAVID · CIK 0001196723 · Chief Administrative Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 101,893 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transaction was conducted under a Rule 10b5-1 plan. Read SEC document |
| July 02, 2018 Filed Jul 3, 2018 19:28 UTC |
Hollingshead JamesPresident, Sleep Business
|
SaleResMed Common Stock | 600 | $102.80 | $61,680.00 |
DisclosureSEC source: 0001140361-18-031231 · doc1.xml · nonDerivative · entry 1 Hollingshead James · CIK 0001570610 · President, Sleep Business 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 60,263 F1 · kind: The transaction was conducted under a Rule10b5-1 Plan. F1 · price: The transaction was conducted under a Rule10b5-1 Plan. F1 · balance_after: The transaction was conducted under a Rule10b5-1 Plan. Read SEC document |
| June 15, 2018 Filed Jun 19, 2018 22:42 UTC |
Sandercock BrettChief Financial Officer
|
SaleResMed Common Stock | 2,000 | $106.76 | $213,520.00 |
DisclosureSEC source: 0001140361-18-029197 · doc1.xml · nonDerivative · entry 1 Sandercock Brett · CIK 0001346064 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 67,072 F1 · kind: The transaction was conducted under a Rule 10b5-1 Plan. Read SEC document |
| June 04, 2018 Filed Jun 4, 2018 21:57 UTC |
PENDARVIS DAVIDChief Administrative Officer
|
Exercise / conversionResMed Common Stock Options · Derivative | 2,810 | $0.00 Strike: $38.98 | $0.00 |
DisclosureSEC source: 0001140361-18-027202 · doc1.xml · derivative · entry 4 PENDARVIS DAVID · CIK 0001196723 · Chief Administrative Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 14,050 Underlying: ResMed Common Stock · 2,810 shares Expires 2019-11-15 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Disposition to issuer for tax withholding on vesting of performance-based restricted stock units granted on 06/01/2017. F4 · derivative.exercise_date: Represents date options first became exercisable. Options vest 1/3 per year. Read SEC document |
| June 04, 2018 Filed Jun 4, 2018 21:57 UTC |
PENDARVIS DAVIDChief Administrative Officer
|
SaleResMed Common Stock | 2,810 | $103.75 | $291,537.50 |
DisclosureSEC source: 0001140361-18-027202 · doc1.xml · nonDerivative · entry 3 PENDARVIS DAVID · CIK 0001196723 · Chief Administrative Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 99,083 F3 · kind: The transaction was conducted under a Rule 10b5-1 plan. Read SEC document |
| June 04, 2018 Filed Jun 4, 2018 21:57 UTC |
PENDARVIS DAVIDChief Administrative Officer
|
Exercise / conversionResMed Common Stock | 2,810 | $38.98 | $109,533.80 |
DisclosureSEC source: 0001140361-18-027202 · doc1.xml · nonDerivative · entry 2 PENDARVIS DAVID · CIK 0001196723 · Chief Administrative Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 101,893 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · kind: The transaction was conducted under a Rule 10b5-1 plan. Read SEC document |
| June 01, 2018 Filed Jun 4, 2018 21:57 UTC |
PENDARVIS DAVIDChief Administrative Officer
|
Tax withholdingResMed Common Stock | 167 | $103.56 | $17,294.52 |
DisclosureSEC source: 0001140361-18-027202 · doc1.xml · nonDerivative · entry 1 PENDARVIS DAVID · CIK 0001196723 · Chief Administrative Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 99,083 F1 · shares: Disposition to issuer for tax withholding on vesting of performance-based restricted stock units granted on 06/01/2017. F2 · balance_after: Includes 145 shares of ResMed stock purchased on April 30, 2018, through the ResMed Employee Stock Purchase Plan. Read SEC document |
| June 01, 2018 Filed Jun 4, 2018 20:20 UTC |
Hollingshead JamesPresident, Sleep Business
|
SaleResMed Common Stock | 600 | $102.80 | $61,680.00 |
DisclosureSEC source: 0001140361-18-027078 · doc1.xml · nonDerivative · entry 1 Hollingshead James · CIK 0001570610 · President, Sleep Business 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 60,863 F1 · kind: The transaction was conducted under a Rule10b5-1 Plan. F1 · price: The transaction was conducted under a Rule10b5-1 Plan. F2 · balance_after: Includes 202 shares of ResMed stock purchased on April 30, 2018, through the ResMed Employee Stock Purchase Plan. Read SEC document |
| May 30, 2018 Filed Jun 1, 2018 16:18 UTC |
SULPIZIO RICHARDDirector
|
Exercise / conversionResMed Common Stock Options · Derivative | 28,403 | $0.00 Strike: $27.58 | $0.00 |
DisclosureSEC source: 0001140361-18-026731 · doc1.xml · derivative · entry 3 SULPIZIO RICHARD · CIK 0001191329 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: ResMed Commmon Stock · 28,403 shares Expires 2018-11-16 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: Represents date options first became exercisable. Options vest on the earlier of (i) the first November 11 following the Grant Date, or (ii) the date of the first (1st) annual meeting of stockholders of the Company following the Grant Date. Read SEC document |
| May 30, 2018 Filed Jun 1, 2018 16:18 UTC |
SULPIZIO RICHARDDirector
|
SaleResMed Common Stock | 28,403 | $102.78 | $2,919,260.34 |
DisclosureSEC source: 0001140361-18-026731 · doc1.xml · nonDerivative · entry 2 SULPIZIO RICHARD · CIK 0001191329 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,420 F1 · price: This transaction was executed in multiple trades at prices ranging from $102.48 to $103.17. The price reported above reflects the weighted average sale price. The reporting person will provide full information regarding the number of shares and prices at which the transaction was effected upon request to the SEC staff, the issuer or the security holder of the issuer. Read SEC document |
| May 30, 2018 Filed Jun 1, 2018 16:18 UTC |
SULPIZIO RICHARDDirector
|
Exercise / conversionResMed Common Stock | 28,403 | $27.58 | $783,354.74 |
DisclosureSEC source: 0001140361-18-026731 · doc1.xml · nonDerivative · entry 1 SULPIZIO RICHARD · CIK 0001191329 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 35,823 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| May 15, 2018 Filed May 17, 2018 00:47 UTC |
Sandercock BrettChief Financial Officer
|
SaleResMed Common Stock | 2,000 | $101.52 | $203,040.00 |
DisclosureSEC source: 0001140361-18-024284 · doc1.xml · nonDerivative · entry 1 Sandercock Brett · CIK 0001346064 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 69,072 F1 · kind: The transaction was conducted under a Rule 10b5-1 Plan. Read SEC document |
| May 08, 2018 Filed May 10, 2018 11:07 UTC |
PACE GARY WDirector
|
Exercise / conversionResMed Stock Options · Derivative | 28,403 | $0.00 Strike: $27.58 | $0.00 |
DisclosureSEC source: 0001140361-18-022661 · doc1.xml · derivative · entry 3 PACE GARY W · CIK 0001184778 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: ResMed Common Stock · 28,403 shares Expires 2018-11-16 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: Represents date options first became exercisable. Read SEC document |
| May 08, 2018 Filed May 10, 2018 11:07 UTC |
PACE GARY WDirector
|
SaleResMed Common Stock | 28,403 | $97.37 | $2,765,600.11 |
DisclosureSEC source: 0001140361-18-022661 · doc1.xml · nonDerivative · entry 2 PACE GARY W · CIK 0001184778 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 100,578 F1 · price: This transaction was executed in multiple trades at prices ranging from $96.99 to $97.87. The price reported above reflects the weighted average sale price. Read SEC document |
| May 08, 2018 Filed May 10, 2018 11:07 UTC |
PACE GARY WDirector
|
Exercise / conversionResMed Common Stock | 28,403 | $27.58 | $783,354.74 |
DisclosureSEC source: 0001140361-18-022661 · doc1.xml · nonDerivative · entry 1 PACE GARY W · CIK 0001184778 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 128,981 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| May 03, 2018 Filed May 5, 2018 00:03 UTC |
PENDARVIS DAVIDChief Administrative Officer
|
Exercise / conversionResMed Common Stock Options · Derivative | 1,922 | $0.00 Strike: $52.02 | $0.00 |
DisclosureSEC source: 0001140361-18-021843 · doc1.xml · derivative · entry 7 PENDARVIS DAVID · CIK 0001196723 · Chief Administrative Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: ResMed Common Stock · 1,922 shares Expires 2021-11-19 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: Represents date options first became exercisable. ISO options vested on the third anniversary of the grant. Read SEC document |
| May 03, 2018 Filed May 5, 2018 00:03 UTC |
PENDARVIS DAVIDChief Administrative Officer
|
Exercise / conversionResMed Common Stock Options · Derivative | 1,951 | $0.00 Strike: $51.25 | $0.00 |
DisclosureSEC source: 0001140361-18-021843 · doc1.xml · derivative · entry 6 PENDARVIS DAVID · CIK 0001196723 · Chief Administrative Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: ResMed Common Stock · 1,951 shares Expires 2020-11-13 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: Represents date options first became exercisable. ISO options vested on the third anniversary of the grant. Read SEC document |
| May 03, 2018 Filed May 5, 2018 00:03 UTC |
PENDARVIS DAVIDChief Administrative Officer
|
Exercise / conversionResMed Common Stock Options · Derivative | 2,810 | $0.00 Strike: $38.98 | $0.00 |
DisclosureSEC source: 0001140361-18-021843 · doc1.xml · derivative · entry 5 PENDARVIS DAVID · CIK 0001196723 · Chief Administrative Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,860 Underlying: ResMed Common Stock · 2,810 shares Expires 2019-11-15 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transaction was conducted under a Rule 10b5-1 plan. F2 · derivative.exercise_date: Represents date options first became exercisable. Options vest 1/3 per year. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.